Luxa Biotechnology

Focus: Luxa Biotechnology is a stem cell therapy company focused on cell therapy treatments, headquartered in Fort Lee, NJ. The company is developing regenerative medicine solutions for unmet medical needs.

Cell Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About Luxa Biotechnology

AI assessmentNot Hiring

No open roles listed right now. Follow Luxa Biotechnology to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

RPESC-RPE-4W

Dry Age-related Macular Degeneration

Phase 1/2

Clinical Trials (1)

NCT04627428Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)

Phase 1/2

Help build intelligence for Luxa Biotechnology

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity in stem cell and cell therapy—a high-growth therapeutic modality with significant unmet medical need
Single focused pipeline program (RPESC-RPE-4W) allows concentrated impact on a high-impact indication (dry AMD)
Early-stage biotech environment offers direct exposure to drug development from preclinical through early clinical stages

Watch Out For

No active job openings reported and minimal disclosed hiring activity suggest limited near-term expansion or potential resource constraints
Pre-revenue stage with undisclosed funding and cash position creates uncertainty around runway and long-term financial stability
Only one Phase 1/2 program in development with no publications or disclosed NIH funding raises questions about scientific validation and external support

Generated by Claude from Luxa Biotechnology's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 1 clinical trial

Top TAs: Ophthalmology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Ophthalmology

1 pipeline

Marketed

Pipeline